Call for Abstract
4th Annual Congress on Drug Discovery & Designing, will be organized around the theme “Accelerate Drug Discovery and identify new methods of Drug Designing”
Drug Discovery Congress is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Drug Discovery Congress
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Anticancer drug, also called antineoplastic drug, any drug that remains effective in the treatment of malignant, or cancerous, disease. There are several major classes of anticancer drugs; these include alkylating agents, antimetabolites, natural products, and hormones. In addition, there are a number of drugs that do not fall within those classes but that demonstrate anticancer activity and therefore are used in the treatment of malignant disease. The term chemotherapy frequently is equated with the use of anticancer drugs, although it more accurately refers to the use of chemical compounds to treat disease generally.
- Track 1-1Chemotherapeutic Drugs
- Track 1-2Cytotoxic and Targeted Therapies
- Track 1-3Treatment strategies of cancer
- Track 1-4Radiotherapy
- Track 1-5Immunotherapy
- Track 1-6Surgery
The anti-infective drugs which have recently been accepted for clinical use, the antiviral agents, following the trend set by anti-bacterials (antibiotics) a few decades ago, have taken the lead. In recent years, more than forty antiviral compounds have been properly approved, more than half of which are used in the treatment of Human Immunodeficiency Virus (HIV) infections (AIDS). Others have been approved for the treatment of herpesvirus infections, hepatitis B and C, and influenza. For other virus infections, i.e. pox (variola, vaccines), haemorrhagic fever virus, picornavirus, flavivirus, papilloma- and adenovirus infections, effective antiviral drugs still have to be developed or submitted to clinical trials. Even for those virus infections that can already be controlled by therapeutic modalities, the quest for additional molecular targets and new treatment strategies should be pursued. The development of antiviral agents requires a multidisciplinary approach including many different fields, such as molecular modelling, medicinal chemistry, biochemistry, pharmacology, toxicology and clinical medicine.
- Track 2-1Anti-viral drugs
- Track 2-2Pharmacogenomics
- Track 2-3Genomics
Clinical trials are experiments done in clinical research. Such eventual biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interferences, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that certification further study and comparison. Clinical trials generate data on safety and efficacy.
The regulatory affairs outsourcing market has been segmented into five major service segments: regulatory affairs; clinical trial applications and product registrations; regulatory writing and publishing; regulatory consulting and legal representation; and others. The market segments have been extensively analysed on the basis of their usefulness, efficacy, generated revenue and geographic coverage. The market size and forecast in terms of USD million for each service type has been provided for the period from 2012 to 2020, considering 2013 as the base year. The report also provides the compounded annual growth rate (CAGR %) for each market segment for the forecast period from 2014 to 2020.
- Track 3-1Biologics and biotechnology
- Track 3-2Regulatory guidelines
- Track 3-3Emerging technology in clinical trials
- Track 3-4Biomarkers & Surrogate Endpoints for Clinical Trials
It is driven by chemistry but gradually guided by pharmacology and the clinical Sciences, drug research has contributed more to the development of medicine during the past century than any other scientific factor. Improving the science of drug development and instruction is important in fulfilling the public health. The advent of molecular biology and, in particular, of genomic sciences is having a deep conclusion on drug discovery. Emphasis is positioned on the contrast between the academic and industrial research operating environments, which can influence the efficacy of research collaboration between the two communities, but which plays such an important role in drug innovation. The strategic challenges that research directors face are also emphasized.
- Track 4-1Pharmacogenetics in Drug Discovery and Development
- Track 4-2Pharmaceutical Industry Perspective
- Track 4-3Historical Perspective
- Track 4-4Accelerated Drug Discovery Perspectives
In discovery process comprises the early phases of research, which are designed to identify an investigational drug and perform primary tests in the lab. This first stage of the process takes almost three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people.These advances offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used alongside diagnostics, clinical trial protocols must be modified and enhanced.
- Track 5-1Recent Developments in Pharmaceutical Field
- Track 5-2Process Chemistry and Drug Manufacturing
- Track 5-3Global Discovery Outsourcing
- Track 5-4Generic Pharmaceuticals: Challenges and Opportunities
- Track 5-5Successful Drug Discovery from the Research Lab to the Marketplace
The central nervous system (CNS) is the part of the nervous system consisting of the brain and spinal cord. The central nervous system is so named because it integrates information it receives from, and coordinates and influences the activity of, all parts of the bodies of bilaterally symmetric animals — that is, all multicellular animals except sponges and radially symmetric animals such as jellyfish — and it contains the majority of the nervous system.
- Track 6-1Recent Patents on CNS Drug Discovery
- Track 6-2Neuro imaging In CNS Drug Discovery
- Track 6-3Neurodegenerative Diseases
Obesity is a extensive condition that affects older people, and also increasing numbers of young people. Obesity and diabetes are reciprocal. Equal to the Centre for Disease Control, of the people who are identified with type II diabetes, between 80-90% are also identified as obese. Diabetes is an associated disorder characterized by chronic high blood glucose levels due to the body's failure to produce sufficient insulin to regulate high glucose levels.
- Obesity stresses intestines of individual cells. Respectively, overeating stresses the membranous network privileged of cells called endoplasmic reticulum.
- In current research diabetes and obesity rates increased 6% to 57%.
- Every three seconds, someone is diagnosed with diabetes.
- Track 7-1Obesity and Diabetic Nephropathy
- Track 7-2Diabetes and Obesity Related Kidney Disease
- Track 7-3Metabolic complications of obesity
- Track 7-4Diabetes and its complications
- Track 7-5Gestational weight gain and diet
- Track 7-6Insulin and islet biology
- Track 7-7Genetics of diabetes
Targeted drug delivery systems have been developed to optimize regenerative techniques. The system is based on a method that delivers a certain amount of a therapeutic agent for a prolonged period of time to a targeted diseased area within the body. This helps maintain the essential plasma and tissue drug levels in the body, thereby preventing any damage to the healthy tissue via the drug. The drug delivery system is highly integrated and requires various disciplines, such as chemists, biologists, and engineers, to join powers to optimize this system.
- Track 8-1Application of targeted Drug Delivery
- Track 8-2Transmucosal Drug Delivery
- Track 8-3Lymphoid Drug Delivery
- Track 8-4Insitu Drug Delivery
- Track 8-5Micelle Drug Delivery
- Track 8-6Hydrogel in Drug Delivery
- Track 8-7Regenerative Techniques
The development of drugs for HIV infection initiated rapidly after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about the best way to achieve this disease. Here we review the current treatment opportunities, consider novel mechanisms that can be exploited for existing drug targets, and explore the potential of novel targets. With a view to the next quarter century, we reflect whether drug resistance can be avoided, which drug classes will be favoured over others, which strategies are most likely to succeed, and the prospective impact of pharmacogenomics and individualized therapy.
- Track 9-1Classes of drugs and mechanism
- Track 9-2Vaccines research and development
- Track 9-3Current pharmaceutical design
- Track 9-4Immunology and strategies towards HIV and retroviral infections
- Track 9-5Nucleoside analogues and molecular mechanisms
Inflammation and Immunology: Many drug discovery researchers focus on inflammation and inflammatory diseases. A significant percentage of the world's population suffers from related afflictions such as asthma, Crohn's disease, rheumatoid arthritis, and atherosclerosis. It is moreover well known that inflammatory processes are also activated in a wide variety of diseases, including cancer.
- Track 10-1Biomarkers in Chronic Inflammatory Disease
- Track 10-2Process of acute inflammation
- Track 10-3Inflammation Targets
- Track 10-4Rheumatoid Arthritis
- Track 10-5Types of Inflammatory Disorders
Nanotechnology has now initiated to revolutionize medicine. Nanotechnology contains the use of materials with fundamental length scales in the nanometre dimension which demonstrate significantly changed properties associated to micron structured materials. Such materials can include particles, fibers, grain sizes, etc. This session highlighted the advancements nanotechnology is making in medicine in such fields as disease prevention, diagnosis, and treatment including (but not limited to) drug delivery, tissue engineering, implants, sensors, cancer treatment, and toxicity.The global market for nanotechnology was valued at $22.9 billion in 2013 and increased to about $26 billion in 2014. This market is expected to reach about $64.2 billion by 2019, a compound annual growth rate (CAGR) of 19.8% from 2014 to 2019.
- Track 11-1Screening and design
- Track 11-2Nanotechnology methods in Drug Design
- Track 11-3Nanotechnology Fundamental Concepts
- Track 11-4Current Research in Nanotechnology
- Track 11-5Drug Delivery using Nanotechnology
- Track 11-6Applications in Nanotechnology
- Track 11-7Nanoparticles
The R&D drive in the pharmaceutical sector is concentrated on development of new drugs, innovative/indigenous processes for known drugs and development of plant-based drugs through investigation of leads from the traditional systems of medicine. In addition, many nutraceuticals are being consumed in unregulated markets for perceived benefits in health care and improvement of quality of life. Natural pharmaceuticals (Naturaceuticals), nutraceuticals and cosmeceuticals are of excessive importance as a reservoir of chemical diversity aimed at new drug discovery and are explored for antimicrobial, cardiovascular, immunosuppressive and anticancer drugs.
New mass spectrometry (MS) methods, collectively known as data independent analysis and hyperactive reaction monitoring, have recently emerged. The analysis of peptides generated by proteolytic breakdown of proteins, known as bottom-up proteomics, functions as the basis for many of the protein research undertaken by mass spectrometry (MS) laboratories. Discovery-based or shotgun proteomics hires data-dependent acquisition (DDA). Herein, a hybrid mass spectrometer first performs a survey scan, from which the peptide ions with the intensity above a predefined threshold value, are stochastically selected, isolated and sequenced by product ion scanning.
New challenges and opportunities for those involved in Computer-Aided Drug Design. These challenges require us to move beyond typical application areas and develop new tools and techniques. This conference will focus on many of the new challenges facing drug design, and seek to set new research directions to address these challenges.
- Track 13-1Biomarkers in drug designing
- Track 13-2Developments & Applications of Mass Spectroscopy
- Track 13-3Steps Involved in CADD
- Track 13-4Drug Design Software
- Track 13-5Computational methods applied to the optimization of binding kinetics
- Track 13-6The application of computational methods to the design of biologics
- Track 13-7Data analysis and visualization techniques to support multi-objective optimization
Regenerative medicine is a division of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or begin normal function". This field holds the promise of engineering damaged tissues and organs via stimulating the body's own repair mechanisms to functionally heal previously permanent tissues or organs.
- Track 14-1Stem Cells
- Track 14-2Gene Therapy
- Track 14-3Tissue Engineering
- Track 14-4Recent Developments in Regenerative Medicine
- Track 14-5Vascular tissue engineering and regeneration
- Track 14-6Organ transplantation and its new techniques
- Track 14-7Advanced developments in artificial organ system
- Track 14-8Regenerative-medicine approach
- Track 14-9Challenges in tissue engineering
The field of structure-based drug design is a rapidly developing area in which many successes have occurred in recent years. The explosion of genomic, proteomic, and structural information has providing hundreds of new targets and opportunities for future drug lead discovery. This review summarizes the process of structure-based drug design and includes, primarily, the choice of a target, the evaluation of a organization of that target, the pivotal questions to consider in choosing a method for drug lead discovery, and evaluation of the drug leads. Key principles in the field of structure-based drug design will be explained through a case study that explores drug design for AmpC β-lactamase.
- Track 15-1Research & Development in Drug Designing
- Track 15-2Drug Targets
- Track 15-3Drug Designing Docking
- Track 15-4Types of Drug Design
In silico methods can help in classifying drug targets via bioinformatics tools.They can also be used to analyse the target structures for probable binding/ active sites, generate candidate molecules, check for their drug likeness, berth these molecules with the target, rank them according to their binding affinities, further optimize the molecules to improve binding appearances. The use of computers and computational methods permeates all aspects of drug discovery today and forms the core of structure-based drug design. High-performance computing, data management software and internet are facilitating the access of huge amount of data generated and transforming the massive complex biological data into effective knowledge in modern day drug discovery process.
- Track 16-1Structural biology
- Track 16-2Collaborative Drug Discovery and secure information sharing
- Track 16-3ADME
- Track 16-4Virtual screening methods
- Track 16-5Intellectual property issues arising from in silico Discovery
- Track 16-6Systems biology considerations and target validation
- Track 16-7Computational approaches for fragment based Drug Discovery
- Track 16-8Automatic scaffold Design and scaffold hopping
- Track 16-9QM/MM, molecular dynamics and free energy methods
Proteomics, the large-scale analysis of proteins, contributes significantly to our understanding of gene function in the post-genomic era. Proteomics can be divided into three main areas: (1) protein micro-characterization for large-scale documentation of proteins and their post-translational changes; (2) 'differential display' proteomics for comparison of protein levels with potential application in a wide range of diseases; and (3) studies of protein–protein interactions using techniques such as mass spectrometry or the yeast two-hybrid system. Proteomics technologies are under continuous progresses and new technologies are introduced.
- Track 17-1Evolutionary bioinformatics
- Track 17-2Structural bioinformatics
- Track 17-3Next generation sequencing
- Track 17-4Bayesian inference for gene expression & proteomics
- Track 17-5High performance computing in bioinformatics
- Track 17-6Web services in bioinformatics